# Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder

> **NCT03045016** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 15 (actual)

## Conditions studied

- Acute Stress Disorder

## Interventions

- **DRUG:** Prazosin, ALPRESS® LP 2,5 et 5 mg

## Key facts

- **NCT ID:** NCT03045016
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-21
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-03-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045016, "Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03045016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*